EAM
CRNX icon

Exome Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Exome Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62,700
Closed -$1.8M – 80
2025
Q2 		$1.8M Buy
62,700
+11,405
+22% +$352K 1.34% 35
2025
Q1 		$1.72M Buy
+51,295
New +$1.92M 1.53% 31

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Exome Asset Management's CRNX Position: Q3 2025 in Review

Exome Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 62,700 shares — an estimated $1.8M sold.

Exome Asset Management first reported a position in CRNX in Q1 2025 and held it in 2 quarters. The position peaked at $1.8M in Q2 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Exome Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Exome Asset Management sold 62,700 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $1.8M.
  • Exome Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Exome Asset Management's Crinetics Pharmaceuticals position peaked at $1.8M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Exome Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.